MetaCap

Alvotech (ALVO) vs Lycia Therapeutics (LYCA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lycia Therapeutics is the larger company by market cap ($1.72 billion vs $1.47 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALVO-10.04%LYCA+10.23%
+12%-3%-18%
Oct 23, 20261 yearNov 20, 2026
ALVO-10.04%LYCA+10.23%
+11%-1%-13%
Oct 19, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALVO versus LYCA key metrics
MetricALVOLYCA
Share price$4.12$33.07
Market cap$1.47B$1.72B
1-day change-3.96%+4.09%
YTD return-19.69%—
1-year return-19.84%—
Forward P/E19.46—
EPS (TTM)$-0.82$-1.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$586.32M—
Revenue growth (YoY)+19.74%—
Net income (latest FY)$27.92M—
Gross margin59.82%—
Operating margin13.34%—
Net margin4.76%—
52-week high$6.53$36.49
52-week low$2.94$22.19
Distance from 52-week high-36.91%-9.37%
Analyst consensusbuy—
Avg. price target upside+82.04%—
Average volume1.13M432.72K
Shares outstanding356.82M52.09M
Employees1,27931
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Alvotech

ALVO stock →

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees

About Lycia Therapeutics

LYCA stock →

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31 employees

ALVO vs LYCA FAQ

Which is bigger, Alvotech or Lycia Therapeutics?

Lycia Therapeutics (LYCA) is larger, with a market capitalization of $1.72B compared with $1.47B for Alvotech (ALVO).

Are Alvotech and Lycia Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons